Global Innovation in Mental Health: The GALENOS Project

Why It Matters

By turning the massive, fragmented mental‑health literature into actionable, living evidence, GALENOS promises faster, more precise treatments and policy decisions, potentially saving billions in research waste and improving patient outcomes worldwide.

Key Takeaways

• GALENOS aims to accelerate global mental‑health innovation using living evidence.
• Evidence overload hampers clinicians; meta‑analysis can pinpoint effective treatments.
• Project emphasizes open‑access, co‑production with patients, and AI integration.
• Cumulative meta‑analysis can reveal treatment benefits years earlier, reducing waste.
• Bottom‑up, mechanism‑focused research targets precision interventions for anxiety, depression, psychosis.

Summary

The video introduces GALENOS, a Wellcome‑funded Global Alliance for Living Evidence on Anxiety, Depression and Psychosis, led by Prof. Andre Cipriani, aiming to transform mental‑health research by continuously updating and synthesizing evidence worldwide.

Cipriani outlines the crisis of information overload—exponential growth of publications, fragmented data, and research waste—making it impossible for clinicians to stay current. He illustrates how cumulative meta‑analysis, as shown with beta‑blocker trials, can identify effective interventions years before conventional practice, highlighting ethical implications of delayed evidence adoption.

The talk emphasizes open‑science principles: co‑production with people with lived experience, open‑access data, and AI‑driven tools to automate evidence synthesis. He cites Niall Boyce’s definition of GALENOS as “literature‑based discovery science in mental health” and stresses the need for mechanism‑focused, precision approaches that integrate human and animal studies.

If successful, GALENOS could streamline policy decisions, reduce redundant trials, and accelerate delivery of personalized treatments for anxiety, depression and psychosis globally, reshaping how mental‑health care is informed by research.

Original Description

Mental disorders are among the top 10 leading causes of health loss worldwide: in 2023, 15% of the world’s population experienced mental disorders and 17% of the total years lived with disability in the world were due to mental disorders. Anxiety, depression and psychosis rank as the most burdensome disorders across all age groups and locations, and 71% of this global burden could be avoided if all people with these disorders accessed optimal treatment.

Join Andrea Cipriani, Professor of Psychiatry, University of Oxford, in conversation with Alan Stein, Director of the Children and Climate Initiative, Blavatnik School of Government, as he discusses how living evidence synthesis is transforming mental health research and accelerating the development of more effective treatments.

In mental health science, there has been frustratingly slow process in developing new treatments, as well as in predicting which treatments will work for whom and in what contexts. To intervene early and deliver optimal care to patients, we need to understand the underlying mechanisms of mental health conditions, develop safe and effective interventions that target these mechanisms, and improve our capabilities in timely diagnosis and reliable prediction of symptom trajectories.

Better synthesis of existing evidence is one way to reduce waste and improve efficiency in research towards these ends. The Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) is funded by Wellcome and tackles the challenges of mental health science research by cataloguing and evaluating the full spectrum of relevant scientific research including both human and preclinical studies in living systematic reviews. GALENOS also allows the mental health community—including patients, carers, clinicians, researchers, funders and policy makers—to better identify the research questions that most urgently need to be answered and accelerate discovery science into effective new interventions.

Illustrative examples from GALENOS and its new strategic collaboration with the Blavatnik School of Governance will be presented.

Blavatnik School of Government,

University of Oxford

http://www.bsg.ox.ac.uk/